ライフサイエンスコーパス: pyrazinamide

1 tant to ethambutol and 217 were resistant to pyrazinamide.

2 s that are likely to be effective as well as pyrazinamide.

3 previously associated with susceptibility to pyrazinamide.

4 ted source for ethambutol, streptomycin, and pyrazinamide.

5 eptible to orally administered isoniazid and pyrazinamide.

6 ne and compared with Bactec MGIT results for pyrazinamide.

7 standard regimen of rifampin, isoniazid, and pyrazinamide.

8 standard regimen of isoniazid, rifampin, and pyrazinamide.

9 t this enzyme is not the immediate target of pyrazinamide.

10 ranging from 0.5 to 16 times the potency of pyrazinamide.

11 tis pncA or pzaA conferred susceptibility to pyrazinamide.

12 imen of isoniazid, rifampin, ethambutol, and pyrazinamide.

13 and particularly with the regimen containing pyrazinamide.

14 nsasii, organisms usually not susceptible to pyrazinamide.

15 ivity of regimens containing a rifamycin and pyrazinamide.

16 d 3-drug regimen of isoniazid, rifampin, and pyrazinamide.

17 to 0.86); and with isoniazid, rifampin, and pyrazinamide, 0.51 (0.24 to 1.08).

18 optimized FDC tablets (rifampicin/isoniazid/pyrazinamide 120/35/130 mg) to children < 6, 6-13, 13-20

19 poB L452P [rifampicin]; pncA 1 bp insertion [pyrazinamide]; 1984 [95% HPD: 1974-1992]) and 10 y (rpoB

20 months (n = 792) or rifampin, 600 mg/d, and pyrazinamide, 20 mg/kg per day, for 2 months (n = 791).

21 icin (38.7-72.9), isoniazid (11.6-26.3), and pyrazinamide (233-429 mg . h/L).

22 -term outcome, by rank of importance, were a pyrazinamide 24-hour area under the concentration-time c

23 h isoniazid and rifampin (ie, MDR TB), 2.2%; pyrazinamide, 3.0%; streptomycin, 6.2%; and ethambutol h

24 terium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-Cl-PZA) displays a broader range of anti

25 in; 258 bp), katG (isoniazid; 205 bp), pncA (pyrazinamide; 579 bp); rpsL (streptomycin; 196 bp), and

26 2, 3, or 4 FDC tablets (rifampicin/isoniazid/pyrazinamide 75/50/150 mg) daily for 4-8, 8-12, 12-16, a

27 ts daily, respectively (rifampicin/isoniazid/pyrazinamide [75/50/150 mg], with or without 100 mg etha

28 ination (FDC) tablet of rifampicin/isoniazid/pyrazinamide; 75/50/150 mg, and suggest a new FDC with r

29 Of patients assigned to rifampin and pyrazinamide, 80% completed the regimen compared with 69

30 hs of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed by 4 months of

31 nds which are both 100-fold more active than pyrazinamide against M. tuberculosis and possess a serum

32 Inclusion of pyrazinamide (aHR 2.00, 95% CI 1.65-2.41) or more drugs

33 hylaxis regimens of isoniazid, rifampin, and pyrazinamide alone or in combination.

34 of regimens containing pretomanid-rifamycin-pyrazinamide among participants with drug-sensitive pulm

35 19 patients (2.4%) assigned to rifampin and pyrazinamide and 26 (3.3%) assigned to isoniazid develop

36 llin, rifampicin, isoniazid, ethambutol, and pyrazinamide and also screen for substitute pharmaceutic

37 parameters, including natural resistance to pyrazinamide and defective pyrazinamidase (PZase) activi

38 aging revealed synergy between isoniazid and pyrazinamide and demonstrated that the activity of pyraz

39 o rifampin, fluoroquinolones, isoniazid, and pyrazinamide and enable the selection of the most approp

40 nt (rifampin and isoniazid for 24 weeks with pyrazinamide and ethambutol for the first 8 weeks) or a

41 n and isoniazid for 6 months reinforced with pyrazinamide and ethambutol in the first 2 months, given

42 Inclusion of pyrazinamide and ethambutol in the regimen (when suscept

43 ic, and toxicodynamic studies are needed for pyrazinamide and ethionamide.

44 The low prevalence of resistance to pyrazinamide and fluoroquinolones among patients with Hr

45 nd South Africa to investigate resistance to pyrazinamide and fluoroquinolones among patients with tu

46 Pyrazinamide and fluoroquinolones are essential antitube

47 There were no cases of resistance to both pyrazinamide and levofloxacin among Hr-TB patients, exce

48 Additional data on pyrazinamide and levofloxacin resistance were available

49 were simulated for isoniazid, rifampicin and pyrazinamide and moxifloxacin.

50 nce is limited on the performance of DST for pyrazinamide and second-line drugs.

51 site reference standard for all drugs except pyrazinamide and streptomycin.

52 al (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emerge

53 g/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethambutol).

54 regimen: 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine followed by 2 mo of rifamp

55 containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin.

56 h regimen consisting of rifampin, isoniazid, pyrazinamide, and ethambutol (control) using a noninferi

57 pervision with 2 mo of rifabutin, isoniazid, pyrazinamide, and ethambutol (given daily, thrice-weekly

58 e treated with regimens containing rifampin, pyrazinamide, and ethambutol +/- a FQ for a median of 9.

59 Isoniazid, pyrazinamide, and ethambutol achieved higher concentrati

60 Isoniazid, pyrazinamide, and ethambutol achieved higher concentrati

61 nt, i.e., 2 mo of daily rifampin, isoniazid, pyrazinamide, and ethambutol followed by 4 mo of rifampi

62 up of patients received isoniazid, rifampin, pyrazinamide, and ethambutol for 8 weeks, followed by 18

63 tuberculosis therapy (rifampicin, isoniazid, pyrazinamide, and ethambutol for the first 2 months foll

64 ith concentrations of isoniazid, rifampicin, pyrazinamide, and ethambutol measured by liquid chromato

65 supervised therapy with isoniazid, rifampin, pyrazinamide, and ethambutol thrice weekly for 8 wk, fol

66 ulation model including rifampin, isoniazid, pyrazinamide, and ethambutol was developed and parameter

67 In all patients isoniazid, pyrazinamide, and ethambutol were added in standard dose

68 ization-recommended doses, exposures to RIF, pyrazinamide, and ethambutol were lower in children than

69 icidal effect rates for isoniazid, rifampin, pyrazinamide, and ethambutol were the same in the HFS-TB

70 tandard 4-drug therapy (isoniazid, rifampin, pyrazinamide, and ethambutol) in Brazil.

71 rst line antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol) is efficient to treat most

72 berculosis drugs (eg, isoniazid, rifampicin, pyrazinamide, and ethambutol) is non-inferior to a 6-mon

73 or standard of care (isoniazid, rifampicin, pyrazinamide, and ethambutol) using sealed opaque envelo

74 /d, respectively, for rifampicin, isoniazid, pyrazinamide, and ethambutol).

75 F), isoniazid [isonicotinylhydrazine (INH)], pyrazinamide, and ethambutol, among other drug therapies

76 y pharmacokinetics of rifampicin, isoniazid, pyrazinamide, and ethambutol, and explore relationships

77 regimen (2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by 6 months of is

78 e [AUC] and Cmax) for rifampicin, isoniazid, pyrazinamide, and ethambutol, in plasma, epithelial lini

79 For rifampicin, pyrazinamide, and ethambutol, the specificity of resista

80 r 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol.

81 r 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol.

82 lates were sensitive to isoniazid, rifampin, pyrazinamide, and ethambutol.

83 arms (63 to rifampicin 35 mg/kg, isoniazid, pyrazinamide, and ethambutol; 59 to rifampicin 10 mg/kg,

84 culosis therapy (oral isoniazid, rifampicin, pyrazinamide, and ethambutol; HRZE), or pretomanid (oral

85 Ertapenem, isoniazid, pyrazinamide, and metronidazole had either a poor or no

86 SQ109; 63 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, and moxifloxacin; and 123 to the control a

87 d resistance to ethambutol, aminoglycosides, pyrazinamide, and quinolone was low.

88 observed for the anti-TB drugs clofazimine, pyrazinamide, and rifampicin at a pixel size of 30 mum.

89 tiple drugs including isoniazid, ethambutol, pyrazinamide, and rifampin increased from 4.3% to 46% of

90 DST for ethambutol, pyrazinamide, and second-line tuberculosis drugs appears

91 SQ109; 57 to rifampicin 20 mg/kg, isoniazid, pyrazinamide, and SQ109; 63 to rifampicin 10 mg/kg, ison

92 re high, whereas the results for ethambutol, pyrazinamide, and streptomycin resistance were more vari

93 ve drugs (isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin), we demonstrate that thi

94 ed odds of treatment success for ethambutol, pyrazinamide, and the group 4 drugs ranged from 1.7 to 2

95 s [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and two alternative dosing strategies: on

96 Rifampin and pyrazinamide are recommended for treatment of latent tub

97 and synthesis of a series of novel quinolyl pyrazinamides as selective and potent sigma2R ligands th

98 Flat dosing of pyrazinamide at 1,000 mg would have permitted an additio

99 Conclusions: Flat dosing of pyrazinamide at 1,000 mg/d would be readily implementabl

100 118.3, clofazimine AUC0-24/MIC of 50.5, and pyrazinamide AUC0-24 of 379 mg x h/L were associated wit

101 standard regimen of isoniazid, rifampin, and pyrazinamide, based on exponential decline regression.

102 nd pretomanid combined with moxifloxacin and pyrazinamide (BPaMZ) or linezolid (BPaL).

103 ulosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis a

104 ml)) and different half-lives (isoniazid and pyrazinamide (C(MAX) = 28,900 ng/ml and T(1/2) = 8.0 hr)

105 especially by 23.11%, 15.22% and 10.14% for pyrazinamide, ciprofloxacin and ofloxacin, respectively

106 arameters to certain drugs-fluoroquinolones, pyrazinamide, clofazimine-were predictive and should be

107 Pretomanid-rifamycin-pyrazinamide combinations are potent in mice but have no

108 ong participants who received rifampicin and pyrazinamide compared with 1.0% (p=0.03) among participa

109 A 1-mug/mL decrease in pyrazinamide concentration was associated with recurrenc

110 Isoniazid and pyrazinamide concentrations were 14.6 (95% CI: 11.2-18.0

111 Isoniazid and pyrazinamide concentrations were 14.6-fold (95% CI, 11.2

112 ce-weekly TB regimen, and low rifampicin and pyrazinamide concentrations were associated with poor ou

113 404 participants, rifampicin, isoniazid, and pyrazinamide concentrations were subtherapeutic in 85%,

114 hild variability of isoniazid, rifampin, and pyrazinamide concentrations: 110 (77%) completed therapy

115 However, we found that pyrazinamide-containing MDR-LTBI regimens often resulted

116 tes due to adverse effects in persons taking pyrazinamide-containing regimens.

117 of 380 participants assigned rifampicin and pyrazinamide (Cox model rate ratio 1.3 [95% CI 0.7-2.7])

118 d in alternate weeks to receive rifampin and pyrazinamide daily for 2 months (n = 307) or isoniazid d

119 nt with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin an

120 ee months (556), or isoniazid, rifampin, and pyrazinamide daily for three months (462).

121 207 (7.7%) patients assigned to rifampin and pyrazinamide developed grade 3 or 4 hepatotoxicity compa

122 of moxifloxacin to isoniazid, rifampin, and pyrazinamide did not affect 2-mo sputum culture status b

123 ,255 participants with 6,978 plasma samples, pyrazinamide displayed sevenfold exposure variability (1

124 Rationale: Optimizing pyrazinamide dosing is critical to improve treatment eff

125 bsence of a rapid, accurate and standardized pyrazinamide drug susceptibility assays is of great conc

126 alyze the essentiality of both isoniazid and pyrazinamide during the first 14 d of therapy.

127 therapy in the mouse model, whereas omitting pyrazinamide during the first 14 d was detrimental.

128 hat the key sterilizing drugs rifampicin and pyrazinamide efficiently penetrate the sites of TB infec

129 st and second-line drugs, including in pncA (pyrazinamide), embB (ethambutol), gyrA (fluoroquinolones

130 2 months of four-drug (isoniazid, rifampin, pyrazinamide, ethambutol) treatment (induction phase) we

131 tible TB (Hr-TB), which includes rifampicin, pyrazinamide, ethambutol, and levofloxacin.

132 estimated the association of DST results for pyrazinamide, ethambutol, and second-line drugs with tre

133 valid drug susceptibility testing (DST) for pyrazinamide, ethambutol, and second-line tuberculosis d

134 B medication exposure, or drug resistance to pyrazinamide, ethambutol, kanamycin, moxifloxacin, ethio

135 onth daily combinations of moxifloxacin with pyrazinamide, ethionamide, or ethambutol were more activ

136 Thus, the old tuberculosis drug pyrazinamide exerts antibacterial activity by acting as

137 zinamide exposure, and relationships between pyrazinamide exposure and efficacy and safety outcomes.

138 cokinetic parameters, risk factors for lower pyrazinamide exposure, and relationships between pyrazin

139 cal and safety outcomes were associated with pyrazinamide exposure, resulting in therapeutic windows

140 Pyrazinamide exposures were similar to those in adults.

141 rifampicin but relatively high isoniazid and pyrazinamide exposures.

142 and rifampin for 3 months, and rifampin and pyrazinamide for 2 months had similar results: 6.2- to 8

143 ntive therapy for 6 months or rifampicin and pyrazinamide for 2 months provided similar overall prote

144 for 24 weeks or twice weekly rifampicin and pyrazinamide for 8 weeks.

145 efficacy of isoniazid versus rifampicin with pyrazinamide for prevention of tuberculosis in HIV-1-pos

146 of isoniazid with 2 months of rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1-ser

147 th rifampin, or treatment with rifampin plus pyrazinamide for those with a positive test result.

148 cts received either rifampin, isoniazid, and pyrazinamide for two months, followed by rifampin and is

149 tionship study of a series of novel quinolyl pyrazinamides for the treatment PDAC.

150 tion was slightly higher in the rifampin and pyrazinamide group (P = .01).

151 toxic adverse events was 20% in the rifampin-pyrazinamide group and 16% in the isoniazid group.

152 nes-rpoB (rifampin), katG (isoniazid), pncA (pyrazinamide), gyrA (ofloxacin/fluoroquinolone), and rrs

153 of isoniazid, rifapentine, moxifloxacin, and pyrazinamide has become part of WHO recommendations.

154 Pyrazinamide has been a mainstay in the multidrug regime

155 Antagonism between isoniazid and pyrazinamide has been demonstrated in a TB treatment mou

156 nent of the mycobacterial cell envelope, and pyrazinamide has no known target.

157 drugs, including isoniazid, ethambutol, and pyrazinamide have also recently been defined.

158 hesis was irreversibly inhibited by 5-chloro-pyrazinamide in a time-dependent fashion.

159 at a susceptibility breakpoint of 100 mug/ml pyrazinamide in MGIT within a cohort of isolates from So

160 f bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in the first 8 weeks of treatment of pulmon

161 The continued use of pyrazinamide in the treatment of tuberculosis in the abs

162 an tuberculosis and that the full benefit of pyrazinamide in this regimen may be realized after just

163 he first-line drugs isoniazid, rifampin, and pyrazinamide in THP-1 cells.

164 hundred fourteen patients received rifampin/pyrazinamide in Wake County, North Carolina, between Dec

165 Pyrazinamide is a pro-drug that is converted into pyrazi

166 Pyrazinamide is a sterilizing first-line tuberculosis dr

167 Pyrazinamide is an important component of both drug-susc

168 nd their mechanisms of action.The antibiotic pyrazinamide is central to tuberculosis treatment regime

169 Resistance to pyrazinamide is largely driven by mutations in pyrazinam

170 nts, a daily 2-month regimen of rifampin and pyrazinamide is similar in safety and efficacy to a dail

171 A alleles that confer clinical resistance to pyrazinamide is unknown.

172 nd 97.1 to 98.2% for ethambutol, rifampicin, pyrazinamide, isoniazid and ofloxacin respectively).

173 , pyrazinamide) or second-line (bedaquiline, pyrazinamide, levofloxacin, linezolid, clofazimine) regi

174 turing bridging halides (Cl (1); Br (2)) and pyrazinamide ligands that enabled the determination of t

175 rifampicin <8 ug/mL, isoniazid <3 ug/mL, and pyrazinamide <20 ug/mL.

176 of patients had Cmax of rifampicin <8 mg/L, pyrazinamide <35 mg/L, and isoniazid <3 mg/L.

177 that the use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of t

178 st 4 months with rifampin, moxifloxacin, and pyrazinamide, mice treated with rifampin, isoniazid, and

179 g pretomanid (formerly known as PA-824), and pyrazinamide (MPa100Z regimen); moxifloxacin, 200 mg pre

180 gimen); moxifloxacin, 200 mg pretomanid, and pyrazinamide (MPa200Z regimen); or the current standard

181 d elsewhere in BALB/c mice, moxifloxacin and pyrazinamide (MZ) combination was not bactericidal beyon

182 1 mM AVG/aminoethoxyvinylglycine, 0.5 mM PZA/pyrazinamide or 0.25 mM AgNO(3)/silver nitrate).

183 first-line (rifampin, isoniazid, ethambutol, pyrazinamide) or second-line (bedaquiline, pyrazinamide,

184 160 participants with TB received isoniazid, pyrazinamide, or rifampicin, components of first-line ch

185 t to capreomycin, rifampin, isoniazid (INH), pyrazinamide, or streptomycin (STR), 4 were resistant to

186 HRZE), or pretomanid (oral 200 mg daily) and pyrazinamide (oral 1500 mg daily) with either oral bedaq

187 nterpretation of MACs for three antibiotics (pyrazinamide, para-aminosalicylic acid, and isoniazid) r

188 redictors of therapy failure or death were a pyrazinamide peak concentration <38.10 mg/L and rifampin

189 ven with oral 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day for 12 weeks, followed by 14 weeks

190 Objectives: We sought to report pyrazinamide pharmacokinetic parameters, risk factors fo

191 pled to determine rifampicin, isoniazid, and pyrazinamide plasma concentrations after 7-8 weeks of th

192 Pyrazinamide plays an important role in tuberculosis tre

193 domized trial was conducted of isoniazid and pyrazinamide plus 1) pretomanid and rifampicin (arm 1),

194 onamide, or ethambutol were more active than pyrazinamide plus ethambutol, a regimen recommended for

195 Participants received isoniazid and pyrazinamide plus: (i) high-dose rifampicin (30 mg/kg) a

196 pin-resistant isolates are also resistant to pyrazinamide, pyrazinamide susceptibility testing is not

197 Testing for susceptibility to pyrazinamide (PZA) and analysis of the pncA gene sequenc

198 is complex were tested for susceptibility to pyrazinamide (PZA) by the ESP (Trek Diagnostic Systems,

199 utol (EMB) (collectively known as SIRE), and pyrazinamide (PZA) drug susceptibility testing was perfo

200 Patients treated with pyrazinamide (PZA) had a significantly shorter tSCC comp

201 utics isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) have been labeled with carbon-11 and

202 Inclusion of pyrazinamide (PZA) in the tuberculosis (TB) drug regimen

203 Pyrazinamide (PZA) is a first line anti-tubercular drug

204 Pyrazinamide (PZA) is a first-line tuberculosis drug tha

205 Pyrazinamide (PZA) is a key antituberculosis drug, yet n

206 Although pyrazinamide (PZA) is a key component of first- and seco

207 Pyrazinamide (PZA) is an antibiotic used in first- and s

208 Pyrazinamide (PZA) is an important antituberculosis drug

209 Pyrazinamide (PZA) is an important first-line drug in al

210 Pyrazinamide (PZA) is an integral component of the short

211 Pyrazinamide (PZA) is considered the pivot drug in all t

212 Pyrazinamide (PZA) is essential in tuberculosis treatmen

213 uberculosis biochemically, but resistance to pyrazinamide (PZA) rendered that diagnosis suspect.

214 Pyrazinamide (PZA) resistance in multidrug-resistant tub

215 mitations of common tests used for detecting pyrazinamide (PZA) resistance in Mycobacterium tuberculo

216 erformance liquid chromatography to identify pyrazinamide (PZA) resistance in Mycobacterium tuberculo

217 bacterium tuberculosis complex that have any pyrazinamide (PZA) resistance, using a confirmatory test

218 Isoniazid (INH), 2 quinolones, and pyrazinamide (PZA) showed intermediate levels of activit

219 ypic determination of the rifampin (RMP) and pyrazinamide (PZA) susceptibilities of M. tuberculosis i

220 A new agar medium to perform pyrazinamide (PZA) susceptibility testing with Mycobacte

221 azinamidase (PZAase)/nicotinamidase converts pyrazinamide (PZA) to ammonia and pyrazinoic acid, which

222 six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes iso

223 Here, we identify pyrazinamide (PZA), a clinical drug used to treat tuberc

224 hin human macrophages affect the activity of pyrazinamide (PZA), a key antibiotic against TB.

225 earances of isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB).

226 noic acid, the bioactive form of the prodrug pyrazinamide (PZA), interrupts biosynthesis of coenzyme

227 al activity of DCP was comparable to that of pyrazinamide (PZA), one of the first-line antituberculos

228 (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA), were determined.

229 Naturally pyrazinamide (PZA)-resistant Mycobacterium bovis and acq

230 (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA).

231 rally resistant to the antituberculosis drug pyrazinamide (PZA).

232 y used in first- and second-line regimens is pyrazinamide (PZA).

233 d (INH), ethambutol (EMB), rifampicin (RIF), pyrazinamide (PZA)], multi-drug resistant TB (MDR-TB) an

234 rument using the 21-day protocol (Bactec 960 pyrazinamide [PZA] protocol).

235 LZD], moxifloxacin [MFX], clofazimine [CFZ], pyrazinamide [PZA], and kanamycin [KAN]) were quantified

236 ) TB identification; and 75.0% and 98.1% for pyrazinamide(r) TB identification.

237 n-resistant (rifampin(r)), isoniazid(r), and pyrazinamide(r) TB.

238 e combination of moxifloxacin, rifampin, and pyrazinamide reduced the time needed to eradicate Mycoba

239 The rifampin/pyrazinamide regimen for latent tuberculosis infection m

240 The rifampin plus pyrazinamide regimen was more likely than the isoniazid

241 3 [CrI, 0.36 to 0.78]), rifampicin-isoniazid-pyrazinamide regimens (OR, 0.35 [CrI, 0.19 to 0.61]), an

242 R, 0.35 [CrI, 0.19 to 0.61]), and rifampicin-pyrazinamide regimens (OR, 0.53 [CrI, 0.33 to 0.84]) wer

243 , mice treated with rifampin, isoniazid, and pyrazinamide required 6 months of treatment before no re

244 We then screened it for pyrazinamide resistance both in vitro and in an infected

245 e of pncA can be used to accurately identify pyrazinamide resistance mutations.

246 Pyrazinamide resistance was assessed in 4972 patients.

247 In all settings, pyrazinamide resistance was significantly associated wit

248 Although pyrazinamide resistance was significantly associated wit

249 tient to identification of BCG, detection of pyrazinamide resistance, and phylogenetic placement was

250 ne DNA-sequencing method to rapidly identify pyrazinamide resistance-causing mutations in GenoLyse-tr

251 pncA to identify variants likely to lead to pyrazinamide resistance.

252 tients died, of whom one had pDST-identified pyrazinamide resistance.

253 ity, and prevalence of both moxifloxacin and pyrazinamide resistance.

254 colleagues characterise the genetic basis of pyrazinamide resistance.

255 of PZAase activity is the major mechanism of pyrazinamide-resistance by M. tuberculosis.

256 IO-MOF-100 delivery system cleared naturally Pyrazinamide-resistant Bacillus Calmette-Guerin, reduced

257 in macrophages NAM and the related compound pyrazinamide restricted growth of bacille Calmette-Gueri

258 3-month regimen of isoniazid, rifampin, and pyrazinamide resulted in fewer clinical benefits and was

259 are treated with antibiotics (isoniazid and pyrazinamide), resulting in no detectable bacilli by org

260 -line drug discontinuation (26.2%, primarily pyrazinamide), second-line drug initiation (30.0%), and

261 mutations on line probe assay and performed pyrazinamide sequencing.

262 ice treated with rifampin, moxifloxacin, and pyrazinamide, similar efficacy was noted whether pyrazin

263 butol; 59 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109; 57 to rifampicin 20 mg/kg, isoniazi

264 (99.2%) isolates that could be assigned true pyrazinamide status with confidence, phenotypic DST had

265 Methods: We analyzed pyrazinamide steady-state pharmacokinetic data using pop

266 daily (5 d/wk) moxifloxacin, ethambutol, and pyrazinamide, supplemented with amikacin during the firs

267 s could not be established for nicotinamide (pyrazinamide surrogate), prothionamide, or ethionamide,

268 Methods for testing pyrazinamide susceptibility are difficult and rarely per

269 r-After-The-Exponential (LATE)-PCR assay for pyrazinamide susceptibility in Mycobacterium tuberculosi

270 isolates are also resistant to pyrazinamide, pyrazinamide susceptibility testing is not routinely per

271 obacterium tuberculosis pncA gene allows for pyrazinamide susceptibility testing.

272 nce experimental and clinical information on pyrazinamide susceptibility.

273 fers both a rapid and accurate prediction of pyrazinamide susceptibility.

274 esults suggest that optimizing the dosing of pyrazinamide, the injectables, and isoniazid for drug-re

275 reatment by the introduction of rifampin and pyrazinamide, the two most potent sterilizing drugs, int

276 71(+) BM-MSCs after 90 days of isoniazid and pyrazinamide therapy that rendered animal's lung noninfe

277 tinic acid, PncA also hydrolyzes the prodrug pyrazinamide to generate the active form of the drug, py

278 e antimycobacterial activity associated with pyrazinamide to include M. avium and M. kansasii, organi

279 Pyrazinamide use for initial treatment for children has

280 a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lu

281 zinamide, similar efficacy was noted whether pyrazinamide was administered for 1 month, 2 months, or

282 Resistance to pyrazinamide was assessed by gene sequencing with the de

283 Rifampin/pyrazinamide was associated with a significantly higher

284 A 2-month regimen of rifampin and pyrazinamide was associated with an increased risk for g

285 d the first-line antituberculosis antibiotic pyrazinamide was less effective.

286 namide and demonstrated that the activity of pyrazinamide was limited to lung lesion, showing the hig

287 Regardless of age, pyrazinamide was responsible for the majority of adverse

288 Pyrazinamide was shown to sterilize only in the intensiv

289 Rifampin plus pyrazinamide was the preferred strategy for treating lat

290 erapy (rifampicin, isoniazid, ethambutol and pyrazinamide) was initiated upon Mycobacterium confirmat

291 combination of moxifloxacin, pretomanid, and pyrazinamide, was safe, well tolerated, and showed super

292 netic parameters of isoniazid, rifampin, and pyrazinamide were identified for each patient.

293 py is dependent on the use of the antibiotic pyrazinamide, which is being threatened by emerging drug

294 clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it increased the average time spent

295 ation-dependent antagonism with rifampin and pyrazinamide, with an adjusted odds ratio for therapy fa

296 Whether pyrazinamide (Z) contributes sterilizing activity beyond

297 ages added to a regimen of isoniazid (H) and pyrazinamide (Z) was assessed.

298 omanid (Pa), combined with an existing drug, pyrazinamide (Z), and a repurposed drug, clofazimine (C)

299 mbinations of rifampicin (R), isoniazid (H), pyrazinamide (Z), ethambutol (E), moxifloxacin (M), and

300 floxacin [M], isoniazid [H], rifampicin [R], pyrazinamide [Z], ethambutol [E]) or the control regimen